12 Mid Cap Stocks Just Made New 52-Week Highs
A small group of mid-cap stocks is showing notable strength, but a look inside the numbers reveals very different stories.
Strength in the mid-cap space is concentrated today, with Health Care Services, Pharmaceuticals, and Automotive Retail each placing 2 names on the 52-week-high list. In total, 12 Mid Cap stocks are at their strongest price of the past year.
The largest company on the list is Illumina (ILMN), with a market value of about $30.1 billion, after a 19.4% gain over the last month while the S&P 500 returned +0.6%. This raises the central question for any high list: is the business performance keeping pace with the stock price? Below are the names making new highs.
The Biggest Names On The List
- 6 Red Days In A Row: Meta Platforms Stock Is Down 11%
- How Will Nucor Stock React To Its Upcoming Earnings?
- 5 Red Days In A Row: Rocket Companies Stock Is Down 14%
- Affirm Stock Slides 16% Over 7 Straight Down Days
- Same Industry, Less Money: What Corpay Offers That Global Payments Does Not
- A 7-Day Losing Streak Has Rubrik Stock Down 18%
The table below shows the 10 largest of the 12 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| ILMN | $30.1 Bil | 3.1% | 3.5% | 19.4% | 92.9% |
| FCNCA | $26.4 Bil | 6.5% | 2.6% | 4.8% | 4.1% |
| RPRX | $25.8 Bil | 0.5% | 0.8% | 6.6% | 67.0% |
| DGX | $25.1 Bil | 8.6% | 8.8% | 16.0% | 30.1% |
| LH | $24.0 Bil | 3.4% | 3.2% | 12.5% | 16.7% |
| JAZZ | $15.8 Bil | 1.8% | 5.2% | 10.7% | 119.1% |
| OHI | $15.1 Bil | 0.7% | 2.2% | 9.8% | 40.4% |
| PAG | $14.2 Bil | 0.5% | 5.3% | 22.0% | 30.3% |
| AIT | $12.8 Bil | 0.8% | 3.6% | 4.0% | 30.8% |
| MUSA | $11.5 Bil | 0.8% | 4.0% | 13.1% | 43.9% |
Which names show business strength to match the stock price?
Royalty Pharma (RPRX) presents a case where the numbers support the new high. Its revenue grew 7.8% over the last twelve months, and it operates with a 67.9% operating margin. This combination of growth and profitability is what investors look for to justify a premium.
In contrast, First Citizens BancShares (FCNCA) is also at a high, but its revenue declined 1.0% over the same period. While it trades at a lower multiple of 11.7 times trailing earnings, a new high on a shrinking top line warrants a closer look.
So what is the disciplined way to read this list?
A 52-week-high list is a map of what is working in the market. Strength often persists. But a high is a price, not a verdict on the business itself. The disciplined move is to treat this list as a starting point for research, not a finish line.
The essential next step is to check whether the business fundamentals, revenue growth, margins, and earnings, justify the stock’s new level. A strong price is only meaningful if a strong business is earning it.
A new high tells you what the market already believes. The harder question is which of these runs management itself is underwriting. Our Guidance Momentum screen tracks exactly that: stocks where the company raised its own forward numbers.
One more pattern worth noticing: 6 of the 12 names are Health Care stocks. When a whole group is making new highs together, a biotech ETF like IBB is one way to own the group’s strength without betting on which single name leads it from here.
New Highs Grow Positions Faster Than Plans Do
A new high is real progress, and it is also how winners grow into outsized positions. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.